Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Posi ...Middle East

Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS) of 18.4 months Safety findings consistent with prior studies with no reports of cytokine release...

Hence then, the article about updated results of phase 3 allele study presented at 66th american society of hematology annual meeting confirm efficacy safety and durability of novel allogeneic cell therapy tabelecleucel in relapsed or refractory epstein barr virus posi was published today ( Saturday 07/12/2024 - 08:36 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Posi )

Also on site :

• 1956 Rock Hits, Recorded on the Same Day, Began Record 11-Week Run at No. 1 for Elvis 70 Years Ago Today
• Walmart's Vintage-Inspired Sideboard Has 'Plenty of Storage' and Looks Like a 'Beautiful' Antique
• 1974 Novel, Written by Best-Selling Author Richard Price, Ranked Among 'Best Coming-of-Age Books' of All Time